Impairment of CYP3A4 capacity in patients receiving danazol therapy: examination on oxidative cortisol metabolism.
Konishi
H
H
Department of Hospital Pharmacy, Shiga University of Medical Science, Otsu, Japan. konishi@belle.shiga-med.ac.jp
Takenaka
A
A
Minouchi
T
T
Yamaji
A
A
D000328:Adult; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D003613:Danazol / Q000009:adverse effects*; D004789:Enzyme Activation / Q000187:drug effects; D004965:Estrogen Antagonists / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000652:urine; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000378:metabolism*; D010084:Oxidation-Reduction; D010865:Pilot Projects
D004965:Estrogen Antagonists; C001380:6 beta-hydroxycortisol; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D003613:Danazol; D006854:Hydrocortisone